共 50 条
Conducting Cancer Control and Survivorship Research via Cooperative Groups: A Report from the American Society of Preventive Oncology
被引:8
|作者:
Palesh, Oxana
[1
]
Demark-Wahnefried, Wendy
[2
]
Mustian, Karen
[3
]
Minasian, Lori
[4
]
Rowland, Julia
[4
]
Sprod, Lisa
[3
]
Janelsins, Michelle
[3
]
Peppone, Luke
[3
]
Sloan, Jeff
[5
]
Engquist, Karen Basen
[6
]
Jones, Lee
[7
]
Buist, Diana
[8
]
Paskett, Electra D.
[9
]
机构:
[1] Stanford Univ, Stanford, CA 94305 USA
[2] Univ Alabama Birmingham, Birmingham, AL USA
[3] Univ Rochester, Ctr Canc, Rochester, NY USA
[4] NCI, Bethesda, MD 20892 USA
[5] Mayo Clin, Rochester, MN USA
[6] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[7] Duke Univ, Med Ctr, Durham, NC USA
[8] Univ Washington, Seattle, WA 98195 USA
[9] Ohio State Univ, Columbus, OH 43210 USA
关键词:
LONG-TERM SURVIVORS;
INDUCED BONE LOSS;
BREAST-CANCER;
CHEMOTHERAPY;
WOMEN;
D O I:
10.1158/1055-9965.EPI-11-0176
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
As the number of cancer survivors expands, the need for cancer control and survivorship research becomes increasingly important. The National Cancer Institute (NCI) Cooperative Groups may offer a viable platform to perform such research. Observational, preventive, and behavioral research can often be performed within the cooperative group setting, especially if resources needed for evaluation are fairly simple, if protocols are easily implemented within the typical clinical setting, and if interventions are well standardized. Some protocols are better suited to cooperative groups than are others, and there are advantages and disadvantages to conducting survivorship research within the cooperative group setting. Behavioral researchers currently involved in cooperative groups, as well as program staff within the NCI, can serve as sources of information for those wishing to pursue symptom management and survivorship studies within the clinical trial setting. The structure of the cooperative groups is currently changing, but going forward, survivorship is bound to be a topic of interest and one that perhaps may be more easily addressed using the proposed more centralized structure. Cancer Epidemiol Biomarkers Prev; 20(5); 1050-5. (C) 2011 AACR.
引用
收藏
页码:1050 / 1055
页数:6
相关论文